Joel C. Barrish
Founder chez Jnana Therapeutics, Inc.
Profil
Dr. Joel C.
Barrish is an Advisor at RA Capital Management LP /Private equity/, a Principal at Kojin Therapeutics, Inc. and a Co-Founder, President & Chief Scientific Officer at Jnana Therapeutics, Inc.
Dr. Barrish was previously employed as a Chief Scientific Officer & Executive VP by Achillion Pharmaceuticals, Inc. and a Vice President & Head-Discovery Chemistry by Bristol Myers Squibb Co.
He received his undergraduate degree from the University of Pennsylvania and a doctorate degree from The Trustees of Columbia University in The City of New York.
Postes actifs de Joel C. Barrish
| Sociétés | Poste | Début |
|---|---|---|
Jnana Therapeutics, Inc.
 Jnana Therapeutics, Inc. BiotechnologyHealth Technology Jnana Therapeutics, Inc. provides drug development services. The firm focuses on immunometabolism changing the metabolic pathways in immune cells to affect function; lysosomal function and mucosal defense. The company was founded by Stuart L. Schreiber, Ramnik Xavier, Joanne Kotz and Joel C. Barrish and is headquartered in Boston, MA. | Founder | 01/01/2017 |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Consultant / Advisor | 01/01/2022 |
Kojin Therapeutics, Inc.
 Kojin Therapeutics, Inc. BiotechnologyHealth Technology Kojin Therapeutics, Inc. operates as a small-molecule therapeutics company. It focuses on translating deep biological insight into the plasticity of human cell states to develop therapeutics for cancer, fibrosis, ischemia and immune modulation. The company was founded by Benjamin Cravatt, Stephanie K. Dougan and Stuart L.Schreiber and is headquartered in the United States. | Corporate Officer/Principal | 01/07/2021 |
Anciens postes connus de Joel C. Barrish
| Sociétés | Poste | Fin |
|---|---|---|
| ACHILLION PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 14/07/2017 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Formation de Joel C. Barrish
| The Trustees of Columbia University in The City of New York | Doctorate Degree |
| University of Pennsylvania | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Entreprise privées | 4 |
|---|---|
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
Jnana Therapeutics, Inc.
Jnana Therapeutics, Inc. BiotechnologyHealth Technology Jnana Therapeutics, Inc. provides drug development services. The firm focuses on immunometabolism changing the metabolic pathways in immune cells to affect function; lysosomal function and mucosal defense. The company was founded by Stuart L. Schreiber, Ramnik Xavier, Joanne Kotz and Joel C. Barrish and is headquartered in Boston, MA. | Health Technology |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Finance |
Kojin Therapeutics, Inc.
Kojin Therapeutics, Inc. BiotechnologyHealth Technology Kojin Therapeutics, Inc. operates as a small-molecule therapeutics company. It focuses on translating deep biological insight into the plasticity of human cell states to develop therapeutics for cancer, fibrosis, ischemia and immune modulation. The company was founded by Benjamin Cravatt, Stephanie K. Dougan and Stuart L.Schreiber and is headquartered in the United States. | Health Technology |
